TARKA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tarka, and what generic alternatives are available?
Tarka is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in TARKA is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tarka
A generic version of TARKA was approved as trandolapril; verapamil hydrochloride by GLENMARK PHARMS LTD on May 5th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TARKA?
- What are the global sales for TARKA?
- What is Average Wholesale Price for TARKA?
Summary for TARKA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Patent Applications: | 4,172 |
| Drug Prices: | Drug price information for TARKA |
| What excipients (inactive ingredients) are in TARKA? | TARKA excipients list |
| DailyMed Link: | TARKA at DailyMed |
Paragraph IV (Patent) Challenges for TARKA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TARKA | Extended-release Tablets | trandolapril; verapamil hydrochloride | 1 mg/240 mg | 020591 | 1 | 2008-02-20 |
| TARKA | Extended-release Tablets | trandolapril; verapamil hydrochloride | 2 mg/180 mg and 2 mg/240 mg | 020591 | 1 | 2007-11-09 |
| TARKA | Extended-release Tablets | trandolapril; verapamil hydrochloride | 4 mg/ 240 mg | 020591 | 1 | 2007-07-24 |
US Patents and Regulatory Information for TARKA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-003 | Oct 22, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-002 | Oct 22, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-001 | Oct 22, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-004 | Oct 22, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARKA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-001 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-002 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-003 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-004 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-002 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-001 | Oct 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TARKA
See the table below for patents covering TARKA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Greece | 78413 | ⤷ Sign Up | |
| Portugal | 76052 | NEUE DERIVATE BICYCLISCHER AMINOSAEUREN VERFAHREN ZU IHRER HERSTELLUNG DIESE ENTHALTENDE MITTEL UND DEREN VERWENDUNG SOWIE NEUE BICYCLISCHE AMINOSAEUREN ALS ZWISCHENSTUFEN UND VERFAHREN ZU DEREN HERSTELLUNG | ⤷ Sign Up |
| Netherlands | 930048 | ⤷ Sign Up | |
| German Democratic Republic | 272035 | VERFAHREN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUBEREITUNG, INSBESONDERE EINER KOMBINATION VON ANGIOTENSIN-CONVERTING-ENZYME-HEMMERN MIT CALZIUMANTAGONISTEN | ⤷ Sign Up |
| Japan | H01301659 | NOVEL BICYCLIC COMPOUND | ⤷ Sign Up |
| New Zealand | 221989 | A MIXTURE OF ACE INHIBITORS AND CALCIUM ANTAGONISTS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARKA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0084164 | SPC/GB93/146 | United Kingdom | ⤷ Sign Up | SPC/GB93/146:, EXPIRES: 20070218 |
| 0265685 | C980030 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919 |
| 0265685 | 99C0001 | Belgium | ⤷ Sign Up | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
| 0265685 | SPC/GB98/047 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
